Plus Therapeutics Faces Delisting Concerns
Ticker: PSTV · Form: 8-K · Filed: Mar 14, 2024 · CIK: 1095981
| Field | Detail |
|---|---|
| Company | Plus Therapeutics, Inc. (PSTV) |
| Form Type | 8-K |
| Filed Date | Mar 14, 2024 |
| Risk Level | high |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $2.5 million, $35 million, $500,000, $1,348,000 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-standards, compliance
Related Tickers: PSBT
TL;DR
PLUS stock might get booted from NYSE American, big trouble ahead.
AI Summary
Plus Therapeutics, Inc. filed an 8-K on March 14, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The company's common stock was previously listed on the NYSE American, but it appears to be facing issues that could lead to its transfer or delisting from the exchange.
Why It Matters
This filing indicates potential delisting from a major exchange, which could significantly impact the stock's liquidity and investor confidence.
Risk Assessment
Risk Level: high — The company is facing potential delisting from a major stock exchange, which poses a significant risk to its operations and stock value.
Key Players & Entities
- PLUS THERAPEUTICS, INC. (company) — Registrant
- NYSE American (company) — Exchange where stock was listed
- March 8, 2024 (date) — Earliest event reported date
- March 14, 2024 (date) — Filing date
FAQ
What specific listing rule or standard has Plus Therapeutics, Inc. failed to satisfy?
The filing does not specify the exact listing rule or standard that Plus Therapeutics, Inc. has failed to satisfy, only that it has received a notice regarding such failure.
What is the date of the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing is March 8, 2024.
On which exchange was Plus Therapeutics, Inc.'s common stock previously listed?
Plus Therapeutics, Inc.'s common stock was previously listed on the NYSE American.
What is the company's principal executive office address?
The company's principal executive offices are located at 4200 Marathon Blvd., Suite 200, Austin, Texas 78756.
What is the Commission File Number for Plus Therapeutics, Inc.?
The Commission File Number for Plus Therapeutics, Inc. is 001-34375.
Filing Stats: 720 words · 3 min read · ~2 pages · Grade level 10.9 · Accepted 2024-03-14 17:00:53
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share PSTV The Nasdaq Capital M
- $2.5 million — ule 5550(b)(1) to maintain a minimum of $2.5 million in stockholders' equity for continued l
- $35 million — a market value of listed securities of $35 million or net income from continuing operation
- $500,000 — et income from continuing operations of $500,000 in the most recently completed fiscal y
- $1,348,000 — 023, disclosed stockholders' equity of ($1,348,000) as of December 31, 2023, and that, as
Filing Documents
- d794768d8k.htm (8-K) — 23KB
- 0001193125-24-068002.txt ( ) — 142KB
- pstv-20240308.xsd (EX-101.SCH) — 3KB
- pstv-20240308_lab.xml (EX-101.LAB) — 18KB
- pstv-20240308_pre.xml (EX-101.PRE) — 11KB
- d794768d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PLUS THERAPEUTICS, INC. Date: March 14, 2024 By: /s/ Marc H. Hedrick, M.D. Name: Marc H. Hedrick, M.D. Title: President and Chief Executive Officer